Company: GRCE
Filing Date: 2025-05-15
Form Type: SCHEDULE 13G/A
Source: 0001104659-25-049671
Chunk: 0

Company: Grace Therapeutics, Inc.
Filing Date: 2025-05-15
Form: SCHEDULE 13G/A
Chunk 0
---
") outstanding as of March 7, 2025 reported in the Issuer's S-3, filed with the SEC on March 10, 2025.

| SCHEDULE 13G |

| CUSIP No. | 00430K865 |

| 1                                                                  |                                                                     Daniel Schneeberger |
| 2                                                                  |                                                                                   -a)(b |
| 3                                                                  |                                                                            Sec Use Only |
| 4                                                                  |                                                                             SWITZERLAND |
| Number of Shares Beneficially Owned by Each Reporting Person With: |                                                                       5          0.00   
                                                                       6  1,501,473.00   
                                                                       7          0.00   
                                                                         8  1,501,473.00 |
| 9                                                                  |                                                                            1,501,473.00 |
| 10                                                                 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) |
| 11                                                                 |                                                                                  9.99 % |
| 12                                                                 |                                                                                      IN |

Comment for Type of Reporting Person:(1) Includes (i) 183,779 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 6,033 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,311,661 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP and Spearhead Insurance Solutions IDF, LLC as of May 14, 2025. Excludes 2,932,081 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. (2) Based on 13,718,106 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of March 7, 2025 reported in the Issuer's S-3, filed with the SEC on March 10, 2025.

| SCHEDULE 13G |

| Item 1. |                                                                                                                                                             |
| (a